US Patent

US8551995 — Kinase inhibitor compounds

Composition of Matter · Assigned to Xcovery Holding Co LLC · Expires 2029-02-09 · 3y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects novel pyridine and pyridazine derivatives that inhibit protein kinases and have potential use in treating disorders such as cancer.

USPTO Abstract

Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US8551995
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-02-09
Drug substance claim: Yes
Drug product claim: No
Assignee: Xcovery Holding Co LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.